These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11801872)

  • 21. Genetic susceptibility testing and prophylactic oophorectomy.
    Berchuck A; Carney ME; Futreal PA
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):159-64. PubMed ID: 10206409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
    Olivier RI; van Beurden M
    Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
    Doren A; Vecchiola A; Aguirre B; Villaseca P
    Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
    van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
    Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
    Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
    Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SEOM clinical guidelines in Hereditary Breast and ovarian cancer.
    Llort G; Chirivella I; Morales R; Serrano R; Sanchez AB; Teulé A; Lastra E; Brunet J; Balmaña J; Graña B;
    Clin Transl Oncol; 2015 Dec; 17(12):956-61. PubMed ID: 26669313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
    Meeuwissen PA; Seynaeve C; Brekelmans CT; Meijers-Heijboer HJ; Klijn JG; Burger CW
    Gynecol Oncol; 2005 May; 97(2):476-82. PubMed ID: 15863147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
    Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.